APA (7th ed.) Citation

Xicheng, W., Yanhong, D., Yanqiao, Z., Tianshu, L., Xianglin, Y., Jianwei, Y., . . . Lin, S. (2026). A Randomized Trial of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or FOLFIRI/Cetuximab in Chinese Patients With BRAFV600E Mutant Metastatic Colorectal Cancer: The NAUTICAL Study. Cancer Medicine, 15(3), 1. https://doi.org/10.1002/cam4.71697

Chicago Style (17th ed.) Citation

Xicheng, Wang, et al. "A Randomized Trial of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or FOLFIRI/Cetuximab in Chinese Patients With BRAFV600E Mutant Metastatic Colorectal Cancer: The NAUTICAL Study." Cancer Medicine 15, no. 3 (2026): 1. https://doi.org/10.1002/cam4.71697.

MLA (9th ed.) Citation

Xicheng, Wang, et al. "A Randomized Trial of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or FOLFIRI/Cetuximab in Chinese Patients With BRAFV600E Mutant Metastatic Colorectal Cancer: The NAUTICAL Study." Cancer Medicine, vol. 15, no. 3, 2026, p. 1, https://doi.org/10.1002/cam4.71697.